{"filing":{"accession_number":"0001193125-26-272562","cik":"0001661998","ticker":"QTTB","company_name":"Q32 Bio Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"d117360d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526272562/d117360d8k.htm"},"events":[{"id":11283,"run_id":9901,"accession_number":"0001193125-26-272562","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Q32 Bio's 2026 Annual Meeting of Stockholders. The filing presents voting results for three proposals: election of Class II directors (Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D.), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory vote on named executive officer compensation. The detailed vote tallies and quorum information (75.71% of shares represented) are characteristic of shareholder vote result disclosures required under Item 5.07.","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7834,"accession_number":"0001193125-26-272562","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Q32 Bio's 2026 Annual Meeting of Stockholders. The filing presents voting results for three proposals: election of Class II directors (Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D.), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory vote on named executive officer compensation. The detailed vote tallies and quorum information (75.71% of shares represented) are characteristic of shareholder vote result disclosures required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:03:06.128226+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7834,"accession_number":"0001193125-26-272562","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Q32 Bio's 2026 Annual Meeting of Stockholders. The filing presents voting results for three proposals: election of Class II directors (Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D.), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory vote on named executive officer compensation. The detailed vote tallies and quorum information (75.71% of shares represented) are characteristic of shareholder vote result disclosures required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:03:06.128226+00:00","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-06-16"}]}